Keywords
Chemotherapy
acute lymphoblastic leukemia
How to Cite
Abstract
Introduction. Acute lymphoid leukemia is the most common childhood neoplasm. There are various treatment protocols, so it is important to know their impact on survival. Material and methods. Comparative study, retrospective cohort. Patients under 16 years of age with a diagnosis of ALL treated with the ALL IC-BFM 2009 protocol or the LLA 2008 scheme were included during January 2020 to November 2023. The patients' medical records were reviewed, and a data collection sheet was used as an instrument. Kaplan Meier survival analysis was used to determine overall survival (OS) and disease-free survival (DFS). Results. 107 patients were included. The age group of 2-9 years was the most prevalent in both groups (57.1% and 63.3%). OS at 32.2 months was 73.6% with the ALL IC BFM 2009 protocol and 43.5% with the LLA 2008 scheme (p=0.03). The DFS at 30.8 months was 82.3% and 51.8% respectively (p=0.04). Discussion. In our study, OS and DFS were greater than 70% for the ALL IC BFM 2009 protocol, these findings being similar to those reported in international literature. Survival with the ALL IC BFM 2009 protocol was superior to the previous institutional protocol.
References
Ward E, DeSanti, C, Robbin, A, Kohler B & Jemal A. (2014). Childhood and adolescent cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(2), 83–103. https://doi.org/10.3322/caac.21219
Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020 Apr 4;395(10230):1146-1162. doi:10.1016/S0140-6736(19)33018-1. 3. Tandon S. Acute leukemia treatment in low- and middle-income countries: Is it time for tailored therapy? Cancer Research, Statistics, and Treatment. 2020;3(3),642-643. https://journals.lww.com/crst/fulltext/2020/03030/acute_leukemia_treatment_in_low__and_middle_income.52.aspx
Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020 Nov 1;105(11):2524-2539. doi: 10.3324/haematol.2020.247031.
Campbell M, Kiss C, Zimmermann M, Riccheri C, Kowalczyk J, Felice MS, Kuzmanovic M, Kovacs G, Kosmidis H, Gonzalez A, Bilic E, Castillo L, Kolenova A, Jazbec J, Popa A, Konstantinov D, Kappelmayer J, Szczepanski T, Dworzak M, Buldini B, Gaipa G, Marinov N, Rossi J, Nagy A, Gaspar I, Stary J, Schrappe M. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. J Clin Oncol. 2023 Jul 1;41(19):3499-3511. doi: 10.1200/JCO.22.01760.
Sunamak EÇ, Özdemir N, Koka A, Yantiri L, Apak H, Celkan T. Comparison of outcomes of children with acute lymphoblastic leukemia treated with BMF protocol across 2 decades. Pediatr Hematol Oncol. 2021 Mar;38(2):134-146. doi:10.1080/08880018.2020.1825573.
Castro-Arechaga S, Ronceros-Salas L, Vega-Centeno S, Moreno, M & Soto A. . Sobrevida global y libre de enfermedad en una cohorte peruana de pacientes con leucemia linfoblástica aguda. Revista Peruana de Medicina Experimental y Salud Pública, 2018;35(3), 416. https://doi.org/10.17843/rpmesp.2018.353.2947
Tello-Vera S, Colchado-Aguilar J & Carpio-Vásquez W. (2018). Supervivencia de pacientes con leucemias agudas en dos hospitales de la seguridad social del Perú. Revista Venezolana de Oncología. 2018; 30(1), 9. https://www.redalyc.org/articulo. oa?id=375653993006
Rojas N, Moreno M, Pizarro M, Aranda L, Arteta C, Eyzaguirre R, Goicochea S, Nieto W, Garcia-Solorzano F, Taype-Rondan A & Timaná R. Guía de Práctica Clínica para el manejo de pacientes con Leucemia Linfoblástica Aguda en el Seguro Social del Perú (EsSalud). Acta Médica Peruana. 2021;38(1), 64-78. https://dx.doi.org/10.35663/amp.2021.381.1038
Seguro Social de Salud - EsSalud. Guía de práctica clínica para el manejo inicial de leucemia linfoblástica aguda. 2019; 29, 29.
Verdezoto S, Estrella B & Robles R. Sobrevida en población pediátrica con leucemia linfoblástica aguda tratada con protocolo ALLIC-BFM de quimioterapia. Revisión sistemática. Revista Eugenio Espejo202217(1),78-97. https://doi.org/10.37135/ee.04.16.09
Ozaeta D, Casalla, A, Martínez L, Castillo A, Baquero O & Cobos O. Supervivencia de los niños con Leucemia Linfoide Aguda manejados con protocolo Basado en ALL-IC-BFM 2009 en Bogotá D.C. Colombia. Pediatría. 2021 53(4), 145-152. https://doi.org/10.14295/rp.v53i4.205
Alecsa MS, Moscalu M, Trandafir LM, Ivanov AV, Rusu C, Miron IC. Outcomes in Pediatric Acute Lymphoblastic Leukemia-A Single-Center Romanian Experience. J Clin Med. 2020 Dec 15;9(12):4052. doi:10.3390/jcm9124052.
Jovanovska A, Trakova-Antevska Z, Kocheva S, Stankovikj S, Panovska-Stavridis I, Dimovski A, Martinova K. Clinical Characteristics and Treatment Results of Childhood Acute Lymphoblastic Leukemia in North Macedonia. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2020 Sep 1;41(2):37-47. doi: 10.2478/prilozi-2020-0031.
Kowalczyk JR, Zawitkowska J, Lejman M, Drabko K, Samardakiewicz M, Matysiak M, Romiszewski M, Balwierz W, Ćwiklińska M, Kazanowska B, Owoc-Lempach J, Wachowiak J, Derwich K, Adamkiewicz-Drożyńska E, Niedźwiecki M, Trelińska J, Młynarski W, Wysocki M, Kołtan A, Szczepański T, Krawczuk-Rybak M, Kitszel A, Wieczorek M, Urasiński T, Ociepa T, Sobol-Milejska G, Mizia-Malarz A, Karolczyk G, Stary J. Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial. Am J Hematol. 2019 Nov;94(11):E307-E310. doi: 10.1002/ajh.25619. Epub 2019 Aug 30.
Zawitkowska J, Lejman M, Romiszewski M, Matysiak M, Ćwiklińska M, Balwierz W, Owoc-Lempach J, Kazanowska B, Derwich K, Wachowiak J, Niedźwiecki M, Adamkiewicz-Drożyńska E, Trelińska J, Młynarski W, Kołtan A, Wysocki M, Tomaszewska R, Szczepański T, Płonowski M, Krawczuk-Rybak M, Urbańska-Rakus J, Machnik K, Ociepa T, Urasiński T, Mizia-Malarz A, Sobol-Milejska G, Karolczyk G, Kowalczyk J. Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia. Sci Rep. 2020 Nov 19;10(1):20168. doi: 10.1038/s41598-020-75860-6
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar